Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma

References

• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–12. doi:10.1038/nrc1014.
   PubMed Web of Science ®Google Scholar
• Johnsen JI, Dyberg C, Wickström M. 2019. Neuroblastoma—A neural crest derived embryonal malignancy. Front Mol Neurosci. 12:433925. doi: 10.3389/fnmol.2019.00009.
   Web of Science ®Google Scholar
• Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi:10.1016/j.hoc.2009.11.011.
   PubMed Web of Science ®Google Scholar
• Greengard EG. Molecularly targeted therapy for neuroblastoma. Children. 2018;5(10):142. doi:10.3390/CHILDREN5100142.
   PubMedGoogle Scholar
• Zage PE. Novel therapies for relapsed and refractory neuroblastoma. Children. 2018;5(11):148. doi:10.3390/CHILDREN5110148.
   PubMedGoogle Scholar
• Shendy NAM, Zimmerman MW, Abraham BJ, Durbin AD. Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights. Cell Rep Med. 2022;3(5):100632. doi:10.1016/J.XCRM.2022.100632.
   PubMedGoogle Scholar
• Pillai M, Jolly MK. Systems-level network modeling deciphers the master regulators of phenotypic plasticity and heterogeneity in melanoma. iScience. 2021;24(10):103111. doi:10.1016/j.isci.2021.103111.
   PubMed Web of Science ®Google Scholar
• Sharma A, Merritt E, Hu X, Cruz A, Jiang C, Sarkodie H, Zhou Z, Malhotra J, Riedlinger GM, De S. Non-genetic intra-tumor heterogeneity is a major predictor of phenotypic heterogeneity and ongoing evolutionary dynamics in lung tumors. Cell Rep. 2019;29(8):2164–2174.e5. doi:10.1016/j.celrep.2019.10.045.
   PubMed Web of Science ®Google Scholar
• Su Y, Bintz M, Yang Y, Robert L, Ng AHC, Liud V, Ribas A, Heath JR, Wei W, Tanay A. Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance. PLoS Comput Biol. 2019;15(6):e1007034. doi:10.1371/journal.pcbi.1007034.
   PubMed Web of Science ®Google Scholar
• Gautier M, Thirant C, Delattre O, Janoueix-Lerosey I. Plasticity in neuroblastoma cell identity defines a noradrenergic-to-mesenchymal transition (Nmt). Cancers Basel. 2021;13(12):2904. doi:10.3390/cancers13122904.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Monkman J, Blick T, Pinto C, Waltham A, Nagaraj SH, Thompson EW. Interrogation of phenotypic plasticity between epithelial and mesenchymal states in breast cancer. J Clin Med. 2019;8(6):893. doi:10.3390/jcm8060893.
   PubMed Web of Science ®Google Scholar
• Chauhan L, Ram U, Hari K, Jolly MK. Topological signatures in regulatory network enable phenotypic heterogeneity in small cell lung cancer. Elife. 2021;10:e64522. doi:10.7554/eLife.64522.
   PubMed Web of Science ®Google Scholar
• Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NKV, Ross RA. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia. 2004;6(6):838. doi:10.1593/NEO.04310.
   PubMed Web of Science ®Google Scholar
• Zeineldin M, Patel AG, Dyer MA. Neuroblastoma: When differentiation goes awry. Neuron. 2022;110(18):2916–2928. doi:10.1016/j.neuron.2022.07.012.
   PubMed Web of Science ®Google Scholar
• Lecca MC, Jonker MA, Kulsoom AU, Uçuç¨uçükosmanoglu AK¨, Van Wieringen W, Westerman BA. Adrenergic to mesenchymal fate switching of neuroblastoma occurs spontaneously in vivo resulting in differential tumorigenic potential. Eur J Mol Clin Med. 2018;1(4):219–226. doi:10.31083/J.JMCM.2018.04.4221.
   Google Scholar
• Thirant C, Peltier A, Durand S, Kramdi A, Louis-Brennetot C, Pierre-Eugène C, Gautier M, Costa A, Grelier A, Zaïdi S, et al. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma. Nat Commun. 2023;14(1):1–18. doi:10.1038/s41467-023-38239-5.
   PubMed Web of Science ®Google Scholar
• Van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49(8):1261–1266. doi:10.1038/ng.3899.
   PubMed Web of Science ®Google Scholar
• Kahlert UD, Joseph JV, Kruyt FAE. EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities. Mol Oncol. 2017;11(7):860–877. doi:10.1002/1878-0261.12085.
   PubMed Web of Science ®Google Scholar
• Lourenco AR, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MK, Levine H, et al. Differential contributions of pre- and post-EMT tumor cells in breast cancer metastasis. Cancer Res. 2020;80(2):163–169. doi:10.1158/0008-5472.CAN-19-1427.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226. doi:10.1016/j.tcb.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49(9):1408–1413. doi:10.1038/ng.3921.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Nayak SP, Hari K, Purkait P, Mandal S, Kishore A, Levine H, Jolly MK. 2021. Immunosuppressive traits of the hybrid epithelial/mesenchymal phenotype. Front Immunol. 12:797261. doi: 10.3389/fimmu.2021.797261.
   PubMed Web of Science ®Google Scholar
• Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A, Lengner CJ. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell. 2021;39(8):1150–1162.e9. doi:10.1016/j.ccell.2021.05.005.
   PubMed Web of Science ®Google Scholar
• Tripathi S, Levine H, Jolly MK. The physics of cellular decision making during epithelial–mesenchymal transition. Annu Rev Biophys. 2020;49(1):1–18. doi:10.1146/annurev-biophys-121219-081557.
   PubMedGoogle Scholar
• van Dijk D, Sharma R, Nainys J, Yim K, Kathail P, Carr AJ, Burdziak C, Moon KR, Chaffer CL, Pattabiraman D, et al. Recovering gene interactions from single-cell data using data diffusion. Cell. 2018;174(3):716–729.e27. doi:10.1016/j.cell.2018.05.061.
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet. 2013;29(10):569–574. doi:10.1016/j.tig.2013.05.010.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740. doi:10.1093/bioinformatics/btr260.
   PubMed Web of Science ®Google Scholar
• Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine J-C, Geurts P, Aerts J, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083–1086. doi:10.1038/nmeth.4463.
   PubMed Web of Science ®Google Scholar
• Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171(7):1611–1624.e24. doi:10.1016/j.cell.2017.10.044.
   PubMed Web of Science ®Google Scholar
• Hari K, Ullanat V, Balasubramanian A, Gopalan A, Jolly MK. Landscape of epithelial mesenchymal plasticity as an emergent property of coordinated teams in regulatory networks. Elife. 2022;11:e76535. doi:10.7554/elife.76535.
   PubMed Web of Science ®Google Scholar
• Chakraborty P, Chen EL, McMullen I, Armstrong AJ, Jolly MK, Somarelli JA. 2021. Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum. Comput Struct Biotechnol J. 19:3842–3851. doi: 10.1016/j.csbj.2021.06.023.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Adati N, Ozawa R, Maeda A, Sakaki Y, Takeda T. Identification and classification of genes regulated by phosphatidylinositol 3-kinase- and TRKB-mediated signalling pathways during neuronal differentiation in two subtypes of the human neuroblastoma cell line SH-SY5Y. BMC Res Notes. 2008;1(1):95. doi:10.1186/1756-0500-1-95.
   PubMedGoogle Scholar
• Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Øra I, Eva A, et al. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer. 2010;9(1):185. doi:10.1186/1476-4598-9-185.
   PubMedGoogle Scholar
• Middelbeek J, Visser D, Henneman L, Kamermans A, Kuipers AJ, Hoogerbrugge PM, Jalink K, van Leeuwen FN. TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation. Oncotarget. 2015;6(11):8760–8776. doi:10.18632/ONCOTARGET.3315.
   PubMedGoogle Scholar
• Gu L, Chu P, Lingeman R, McDaniel H, Kechichian S, Hickey RJ, Liu Z, Yuan YC, Sandoval JA, Fields GB, et al. The mechanism by which MYCN amplification confers an enhanced sensitivity to a PCNA-Derived cell permeable peptide in neuroblastoma cells. EBioMedicine. 2015;2(12):1923–1931. doi:10.1016/J.EBIOM.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011;108(8):3336–3341. doi:10.1073/pnas.1012351108.
   PubMed Web of Science ®Google Scholar
• Ikegaki N, Shimada H, Fox AM, Regan PL, Jacobs JR, Hicks SL, Rappaport EF, Tang XX. Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci U S A. 2013;110(15):6097–6102. doi:10.1073/pnas.1118262110.
   PubMed Web of Science ®Google Scholar
• Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, Gray NS, George RE. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene. 2016;35(28):3681–3691. doi:10.1038/ONC.2015.434.
   PubMed Web of Science ®Google Scholar
• Hari K, Harlapur P, Saxena A, Girish A, Levine H, Jolly MK. 2023. Low dimensionality of phenotypic space as an emergent property of coordinated teams in biological regulatory networks. bioRxiv. doi:10.1101/2023.02.03.526930.
   PubMedGoogle Scholar
• Khazeem MM, Casement JW, Schlossmacher G, Kenneth NS, Sumbung NK, Chan JYT, McGow JF, Cowell IG, Austin CA. TOP2B is required to maintain the adrenergic neural phenotype and for ATRA-Induced differentiation of SH-SY5Y neuroblastoma cells. Mol Neurobiol. 2022;59(10):5987–6008. doi:10.1007/s12035-022-02949-6.
   PubMed Web of Science ®Google Scholar
• Van Groningen T, Akogul N, Westerhout EM, Chan A, Hasselt NE, Zwijnenburg DA, Broekmans M, Stroeken P, Haneveld F, Hooijer GKJ, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat Commun. 2019;10(1). doi:10.1038/S41467-019-09470-W.
   PubMedGoogle Scholar
• Forrest MP, Waite AJ, Martin-Rendon E, Blake DJ. Knockdown of human TCF4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation. PLoS ONE. 2013;8(8):e73169. doi:10.1371/JOURNAL.PONE.0073169.
   PubMed Web of Science ®Google Scholar
• Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, He S, Krill-Burger JM, Root DE, Vazquez F, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50(9):1240. doi:10.1038/S41588-018-0191-Z.
   PubMed Web of Science ®Google Scholar
• Tao L, Moreno‐Smith M, Ibarra‐García‐Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B, et al. CHAF1A blocks neuronal differentiation and promotes neuroblastoma oncogenesis via metabolic reprogramming. Adv Sci. 2021;8(19):2005047. doi:10.1002/advs.202005047.
   Web of Science ®Google Scholar
• Treiman M, Caspersen C, Christensen SB. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2±ATPases. Trends Pharmacol Sci. 1998;19(4):131–135. doi:10.1016/S0165-6147(98)01184-5.
   PubMed Web of Science ®Google Scholar
• Bensalel J, Xu H, Lu ML, Capobianco E, Wei J. RNA-seq analysis reveals significant transcriptome changes in huntingtin-null human neuroblastoma cells. BMC Med Genomics. 2021;14(1):176. doi:10.1186/S12920-021-01022-W.
   PubMed Web of Science ®Google Scholar
• Slade RF, Hunt DA, Pochet MM, Venema VJ, Hennigar RA. Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines. Anticancer Res. 2003;23(2B):1235–1243.
   PubMed Web of Science ®Google Scholar
• Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, Munksgaard Persson M, Hultenby K, Lehtiö J, Einvik C, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci USA. 2013;110(25):10258–10263. doi:10.1073/pnas.1222404110.
   PubMed Web of Science ®Google Scholar
• Muralidharan S, Sehgal M, Soundharya R, Mandal S, Majumdar SS, Yeshwanth M, Saha A, Jolly MK. PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas. Curr Oncol. 2022;29(11):8285–8301. doi:10.3390/CURRONCOL29110654.
   PubMed Web of Science ®Google Scholar
• Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889–904. doi:10.1080/14737140.2017.1364995.
   PubMed Web of Science ®Google Scholar
• Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022;3(8):976–993. doi:10.1038/s43018-022-00405-x.
   PubMedGoogle Scholar
• Jansky S, Sharma AK, Körber V, Quintero A, Toprak UH, Wecht EM, Gartlgruber M, Greco A, Chomsky E, Grünewald TGP, et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nat Genet. 2021;53(5):683–693. doi:10.1038/s41588-021-00806-1.
   PubMed Web of Science ®Google Scholar
• Dong R, Yang R, Zhan Y, Lai H-D, Ye C-J, Yao X-Y, Luo W-Q, Cheng X-M, Miao J-J, Wang J-F, et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell. 2020;38(5):716–733.e6. doi:10.1016/j.ccell.2020.08.014.
   PubMed Web of Science ®Google Scholar
• Kameneva P, Artemov AV, Kastriti ME, Faure L, Olsen TK, Otte J, Erickson A, Semsch B, Andersson ER, Ratz M, et al. Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat Genet. 2021;53(5):694–706. doi:10.1038/s41588-021-00818-x.
   PubMed Web of Science ®Google Scholar
• Rohrer H. Linking human sympathoadrenal development and neuroblastoma. Nat Genet. 2021;53(5):593–594. doi:10.1038/s41588-021-00845-8.
   PubMed Web of Science ®Google Scholar
• Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973;33(11):2643–2652.
   PubMed Web of Science ®Google Scholar
• Pasani S, Sahoo S, Jolly MK. Hybrid E/M phenotype(s) and stemness: a mechanistic connection embedded in network topology. J Clin Med. 2021;10(1):60. doi:10.1101/2020.10.18.341271.
   Web of Science ®Google Scholar
• Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol. 2007;17(3):241–247. doi:10.1016/j.semcancer.2006.04.006.
   PubMed Web of Science ®Google Scholar